Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01112527 · ClinicalTrials.gov registry record · Phase 2

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
58
Enrollment target
4
Study locations

NCT01112527 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that has completed, run by Massachusetts General Hospital. The registered enrollment target is 58 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (47% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01112527, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
58 participants
Enrollment target
4
Study locations

Study Summary

There are three arms to this study (A, B and C) The purpose of this research study during Arm A is to see how much of PF-00299804 gets into the brain tumor. For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells. We will determine how much PF-00299804 gets into the brain tumor by obtaining a sample of the tumor from the surgery that the participant already has scheduled. The purpose of this research study during Arm B and C, is to determine how well PF-00299804 works in killing cancer cells. PF-00299804 works by binding to specific proteins found on the surface of some cancer cells that promote a growth signal. Blocking this signal from reaching its target on the cancer cells may slow or stop the cancer from growing.

Conditions Studied

Glioblastoma Glioblastoma Multiforme GBM

Interventions

  • DRUG PF-00299804

Study Locations (4)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Hospital - Detroit

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2010-04
Est. Completion 2015-09
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01112527

The ClinicalTrials.gov registry entry for NCT01112527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (47% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which PF-00299804 is the first listed.

NCT01112527 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, Ohio.

Frequently Asked Questions

What is clinical trial NCT01112527 about?

NCT01112527 is a clinical study titled "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma". There are three arms to this study (A, B and C) The purpose of this research study during Arm A is to see how much of PF-00299804 gets into the brain tumor. For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor a...

What is the current status of trial NCT01112527?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2010-04. Estimated completion is 2015-09.

What conditions does trial NCT01112527 study?

This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, GBM.

What interventions are being tested in trial NCT01112527?

The interventions under investigation include: PF-00299804 (DRUG).

Who is sponsoring clinical trial NCT01112527?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01112527 being conducted?

This trial has 4 study locations across Massachusetts, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Glioblastoma Multiforme

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.